Humoral profiles of toddlers and young children following SARS-CoV-2 mRNA vaccination
暂无分享,去创建一个
G. Alter | W. Shreffler | A. Fasano | L. Wood | A. Edlow | L. Yonker | Yixiang Deng | B. Julg | A. Kane | N. Nziza | Nitya Jain | Jameson P. Davis | Melina Demokritou | Ryan P. McNamara | Z. Swank | Anagha P. Chitnis | Navneet Dhanoa | Naomi Dulit-Greenberg | Tina Chen | Bruce Horwitz | Ryan McNamara
[1] David Cox. What do we know about covid-19 and children? , 2023, BMJ.
[2] S. Bhatt,et al. Assessment of COVID-19 as the Underlying Cause of Death Among Children and Young People Aged 0 to 19 Years in the US , 2023, JAMA network open.
[3] J. Tomassini,et al. Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age , 2022, The New England journal of medicine.
[4] S. Saydah,et al. Post–COVID-19 Symptoms and Conditions Among Children and Adolescents — United States, March 1, 2020–January 31, 2022 , 2022, MMWR. Morbidity and mortality weekly report.
[5] J. W. Chen,et al. BNT162b2 induces robust cross-variant SARS-CoV-2 immunity in children , 2022, npj Vaccines.
[6] D. Montefiori,et al. Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age , 2022, The New England journal of medicine.
[7] Manish M Patel,et al. Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents , 2022, The New England journal of medicine.
[8] M. Rämet,et al. Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age , 2021, The New England journal of medicine.
[9] M. Exline,et al. Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity. , 2021, JAMA.
[10] R. Pajon,et al. Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents , 2021, The New England journal of medicine.
[11] C. Conrad,et al. Pre-activated antiviral innate immunity in the upper airways controls early SARS-CoV-2 infection in children , 2021, Nature Biotechnology.
[12] D. Lauffenburger,et al. Humoral signatures of protective and pathological SARS-CoV-2 infection in children , 2021, Nature Medicine.
[13] J. Mascola,et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.
[14] C. del Rio,et al. Assessment of Deaths From COVID-19 and From Seasonal Influenza. , 2020, JAMA internal medicine.
[15] Liang Jin,et al. The Effects of Secretory IgA in the Mucosal Immune System , 2020, BioMed research international.
[16] M. Carrington,et al. IgG3 enhances neutralization potency and Fc effector function of an HIV V2-specific broadly neutralizing antibody , 2019, PLoS pathogens.
[17] C. Pechmann,et al. Policy and Research Related to Consumer Rebates: A Comprehensive Review , 2013 .
[18] G. Alter,et al. A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation☆ , 2019, Journal of immunological methods.
[19] G. Alter,et al. A versatile high-throughput assay to characterize antibody-mediated neutrophil phagocytosis , 2019, Journal of immunological methods.
[20] J. Lopez-Garcia. The importance of being specific , 2019, European journal of pain.
[21] S. Kent,et al. Role of IgG3 in Infectious Diseases. , 2019, Trends in immunology.
[22] A. McMichael,et al. Evolution of the immune system in humans from infancy to old age , 2015, Proceedings of the Royal Society B: Biological Sciences.
[23] C. Bailey-Kellogg,et al. High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples. , 2012, Journal of immunological methods.
[24] A. Díaz,et al. Age effects on B cells and humoral immunity in humans , 2011, Ageing Research Reviews.
[25] D. Irvine,et al. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. , 2010, Journal of immunological methods.
[26] C. Weyand,et al. T cell development and receptor diversity during aging. , 2005, Current opinion in immunology.